Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Uropathogenic Escherichia coli (UPECs) is a leading cause for urinary tract infections (UTI), accounting for 70-90 % of community or hospital-acquired bacterial infections owing to high recurrence, imprecision in diagnosis and management, and increasing prevalence of antibiotic resistance. Current methods for clinical UPECs detection still rely on labor-intensive urine cultures that impede rapid and accurate diagnosis for timely UTI therapeutic management. Herein, we developed a first-in-class near-infrared (NIR) UPECs fluorescent probe (NO-AH) capable of specifically targeting UPECs through its collaborative response to bacterial enzymes, enabling locoregional imaging of UTIs both in vitro and in vivo. Our NO-AH probe incorporates a dual protease activatable moiety, which first reacts with OmpT, an endopeptidase abundantly present on the outer membrane of UPECs, releasing an intermediate amino acid residue conjugated with a NIR hemicyanine fluorophore. Such liberated fragment would be subsequently recognized by aminopeptidase (APN) within the periplasm of UPECs, activating localized fluorescence for precise imaging of UTIs in complex living environments. The peculiar specificity and selectivity of NO-AH, facilitated by the collaborative action of bacterial enzymes, features a timely and accurate identification of UPECs-infected UTIs, which could overcome misdiagnosis in conventional urine tests, thus opening new avenues towards reliable UTI diagnosis and personalized antimicrobial therapy management.

Download full-text PDF

Source
http://dx.doi.org/10.1002/anie.202406843DOI Listing

Publication Analysis

Top Keywords

locoregional imaging
8
urinary tract
8
bacterial enzymes
8
imaging utis
8
upecs
6
enzymes synergy
4
synergy bacteria
4
bacteria specific
4
specific molecular
4
molecular probe
4

Similar Publications

Aims: Cardiac tumors are aggressive and asymptomatic in early stages, causing late diagnosis and locoregional metastasis. Currently, the standard of care uses gadolinium-based contrast agents for MRI, and the associated hypersensitivity reactions are a significant concern, such as gadolinium deposition disease. In addition, the proximity of cardiac lesions closer to vital structures complicates surgical interventions.

View Article and Find Full Text PDF

Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor with variable clinical presentation, posing both diagnostic and therapeutic challenges. Disease recurrence is common and may manifest solely as elevated tumor markers in the absence of clinical findings or positive morphological imaging. We present the case of a 56-year-old woman diagnosed with MTC in 2011, treated with total thyroidectomy and adjuvant therapy.

View Article and Find Full Text PDF

The role of brain MR and FDG-PET in the diagnosis of neurodegenerative disease.

Eur Radiol

September 2025

Department of Radiology and Imaging Sciences, University of Utah, 30N Mario Capecchi Drive, 2 South, Salt Lake City, UT, USA.

Alzheimer disease (AD) is the most common dementing disorder, affecting 55 million people worldwide. Brain MRI plays an integral role in the diagnostic evaluation of patients with cognitive symptoms. When interpreting brain MRI for cognitive impairment, radiologists should assess the following four key features: (1) white matter ischemic burden, (2) structural changes to suggest normal pressure hydrocephalus, (3) locoregional pattern of brain atrophy, and (4) presence of microhemorrhage or superficial siderosis, particularly for determining eligibility for anti-amyloid monoclonal antibody (MAB) treatment when appropriate.

View Article and Find Full Text PDF

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, necessitating innovative treatment strategies. Surgical resection and liver transplantation continue to be the gold standards for early-stage HCC; however, advances in imaging and minimally invasive techniques have improved patient selection and outcomes. Additionally, the emergence of targeted therapies and immunotherapy has transformed the treatment landscape for advanced HCC.

View Article and Find Full Text PDF

Introduction And Objectives: To evaluate the safety and efficacy of transcatheter arterial chemoembolization (TACE) combined with intra-arterial bevacizumab infusion in patients with advanced hepatocellular carcinoma (HCC).

Patients And Methods: In this prospective randomized controlled trial, 120 patients with advanced HCC (stages Ib-IIIb) were enrolled between March 2021 and October 2023 and randomized to receive TACE alone (control group, n=60) or TACE plus intra-arterial bevacizumab (combined group, n=60). Tumor perfusion parameters were assessed via dynamic contrast-enhanced MRI (DCE-MRI), while VEGF and SDF-1 levels were measured using ELISA.

View Article and Find Full Text PDF